We caught up with Kelly Knupp (University of Colorado, Anschutz Medical Campus, Children’s Hospital Colorado, CO, USA) to discuss the use of fenfluramine for the reduction of seizures associated with Lennox-Gastaut syndrome. (Clinical Trial Identifier: NCT03355209). The abstract ‘Efficacy and safety of FINTEPLA (fenfluramine) for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized, double-blind, placebo-controlled clinical trial.’ (ABSTRACT NUMBER: 852) was presented at the virtual AES 2020, 4-8 December 2020.
Questions
- Could you tell us a little about Lennox-Gastaut syndrome (LGS) and the unmet needs in its treatment? (0:15)
- What is the rationale for the use of fenfluramine in the treatment of LGS? (1:45)
- What were the aims and design of the recent Phase III study investigating fenfluramine in the treatment of LGS? (2:23)
- What were the efficacy and safety findings of this study? (3:59)
Disclosures: Kelly G Knupp has received research funding from: zogenix, west therapeutics, stoke, encoded, eisai and consulting fees from: The epilepsy study consortium, zogenix, stoke, encoded, eisai, GW, arena, epygenix.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AES 2020, 4-8 December, 2020 (Virtual).
